Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going

Bibliography

• Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013;190:3839-47
   PubMed Web of Science ®Google Scholar
• Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol 2013;735:1-22
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64
   PubMed Web of Science ®Google Scholar
• Risitano AM. Paroxysmal nocturnal hemoglobinuria. In: Silverberg D, editor. Anemia. InTech, Rijeka, Croatia; 2012. p. 331-74
   Google Scholar
• Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259:1318-20
   PubMed Web of Science ®Google Scholar
• Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-11
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A. Decay accelerating factor (CD55). Curr Top Microbiol Immunol 1992;178:7-30
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A, Burge J, Fearon DT, et al. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982;129(1):184-9
   PubMed Web of Science ®Google Scholar
• Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990;71(1):1-9
   PubMed Web of Science ®Google Scholar
• Holguin MH, Fredrick LR, Bernshaw NJ, et al. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989;84:7-17
   PubMed Web of Science ®Google Scholar
• Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-9
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;114:1840-7
   Google Scholar
• Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-8
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786-92
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med 2014;370(7):632-9
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009;113:4094-100
   PubMed Web of Science ®Google Scholar
• Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010;95:567-73
   PubMed Web of Science ®Google Scholar
• Marotta S, Giagnuolo G, Basile S, et al. Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. J Hematol Thromb Dis 2014;2(1):128
   Google Scholar
• Hillmen P, Muus P, Roth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013;162(1):62-73
   PubMed Web of Science ®Google Scholar
• Rondelli T, Risitano AM, Peffault de Latour LR, et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica 2014;99(2):262-6
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT01624636 [10 June 2014]
   Google Scholar
• Adienne Pharma & Biotech. 2014. Available from: http://www.adienne.com/en/rd/pipeline/mubodina®.html [5 April 2015]
   Google Scholar
• Marzari R, Sblattero D, Macor P, et al. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol 2002;32(10):2773-82
   PubMed Web of Science ®Google Scholar
• Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011;48(14):1631-42
   PubMed Web of Science ®Google Scholar
• Nunn MA, Sharma A, Paesen GC, et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 2005;174(4):2084-91
   PubMedGoogle Scholar
• Roversi P, Lissina O, Johnson S, et al. The structure of OMCI, a novel lipocalin inhibitor of the complement system. J Mol Biol 2007;369(3):784-93
   PubMedGoogle Scholar
• Barratt-Due A, Thorgersen EB, Lindstad JK, et al. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J Immunol 2011;187(9):4913-19
   PubMedGoogle Scholar
• Weston-Davies WH, Nunn MA, Pinto FO, et al. Clinical and immunological characterisation of coversin, a novel small protein inhibitor of complement C5 with potential as a therapeutic agent in PNH and other complement mediated disorders. Blood 2014;124:4280
   Web of Science ®Google Scholar
• Josephson K, Ricardo A, Szostak JW. mRNA display: from basic principles to macrocycle drug discovery. Drug Discov Today 2014;19(4):388-99
   PubMed Web of Science ®Google Scholar
• Ricardo A, Arata M, DeMarco S, et al. Development of RA101348, a potent cyclic peptide inhibitor of C5 for complement-mediated diseases. Blood 2014;124:2936
   Web of Science ®Google Scholar
• Cox JC, Rajendran M, Riedel T, et al. Automated acquisition of aptamer sequences. Comb Chem High Throughput Screen 2002;5(4):289-99
   PubMedGoogle Scholar
• Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol 2013;6(5):565-79
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00950638 [5 November 2013]
   Google Scholar
• Drolet DW, Zhang C, O’Connell DJ, et al. SOMAmer inhibitors of the complement system [abstract 23]. Paper presented at: 7th International Conference on Complement Therapeutics; 6 – 11 June 2014; Olympia; Aegean Conferences 82
   Google Scholar
• Feldwisch J, Tolmachev V. Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol 2012;899:103-26
   PubMedGoogle Scholar
• Strömberg P. Introducing SOBI002, a small affibody-ABD fusion protein targeting complement component C5 [abstract 30]. Paper presented at: 7th International Conference on Complement Therapeutics; 6 – 11 June 2014; Olympia; Aegean Conferences 82
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT02083666 [7 November 2014]
   Google Scholar
• Borodovsky A, Yucius K, K Sprague A, et al. Development of RNAi therapeutics targeting the complement pathway. Blood 2013;122(21):2471
   Google Scholar
• Borodovsky A, Yucius K, Sprague A, et al. Aln-CC5, an investigational RNAi therapeutic targeting C5 for complement inhibition. Blood 2014;124:1606
   Google Scholar
• Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 1996;157(2):884-91
   PubMed Web of Science ®Google Scholar
• Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008;632:273-92
   PubMedGoogle Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00473928 [16 March 2010]
   Google Scholar
• Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013;190(8):3839-47
   PubMedGoogle Scholar
• Kaudlay P, Hua H, He G, et al. Red cell complement loading in PNH patients on eculizumab is associated with a C3 polymorphism which influences C3 function, predicts for increased extravascular hemolysis and provides a rationale for C3 inhibition. Blood 2013;122(21):2466
   Google Scholar
• Qu H, Magotti P, Ricklin D, et al. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol 2011;48(4):481-9
   PubMed Web of Science ®Google Scholar
• Qu H, Ricklin D, Bai H, et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2013;218(4):496-505
   PubMedGoogle Scholar
• Magotti P, Ricklin D, Qu H, et al. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J Mol Recognit 2009;22(6):495-505
   PubMed Web of Science ®Google Scholar
• Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014;123(13):2094-101
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest 2015;45(4):423-40
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT02264639 [25 November 2014]
   Google Scholar
• Khera R, Das N. Complement receptor 1: disease associations and therapeutic implications. Mol Immunol 2009;46(5):761-72
   PubMed Web of Science ®Google Scholar
• Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol 1982;129(5):2051-60
   PubMedGoogle Scholar
• Medof ME, Nussenzweig V. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J Exp Med 1984;159(6):1669-85
   PubMed Web of Science ®Google Scholar
• Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981;153(5):1138-50
   PubMed Web of Science ®Google Scholar
• Whaley K, Ruddy S. Modulation of the alternative complement pathway by β1H globulin. J Exp Med 1976;144:1147-63
   PubMed Web of Science ®Google Scholar
• Ricklin D and Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013;190(8):3831-8
   PubMedGoogle Scholar
• Pratt JR, Hibbs MJ, Laver AJ, et al. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 1996;149(6):2055-66
   PubMedGoogle Scholar
• Zhang Y, Nester CM, Holanda DG, et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 2013;24(11):1820-9
   PubMedGoogle Scholar
• Smith RJH, Xiao H, Nester CM, et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy [abstract 37]. Paper presented at: 7th International Conference on Complement Therapeutics; 6 – 11 June 2014; Olympia; Aegean Conferences 82
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT01791686 [6 March 2014]
   Google Scholar
• Smith RA. Membrane-targeted complement inhibitors. Mol Immunol 2012;38:249-55
   Google Scholar
• Sacks S, Karegli J, Farrar CA, et al. Targeting complement at the time of transplantation. Adv Exp Med Biol 2013;735:247-55
   PubMed Web of Science ®Google Scholar
• International Standard Randomised Controlled Trial Number Register. 2014. Available from: http://www.controlled-trials.com/ISRCTN49958194 [3 August 2012]
   Google Scholar
• Holers M, Banda N, Mehta G, et al. The human complement receptor 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertase, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity [abstract #230]. XXIV International Complement Workshop; 10 – 15 October 2012; Chania
   Google Scholar
• Risitano AM, Notaro R, Pascariello C, et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012;119(26):6307-16
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01335165 [21 May 2014]
   Google Scholar
• Schmidt CQ, Bai H, Lin Z, et al. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol 2013;190(11):5712-21
   PubMed Web of Science ®Google Scholar
• Hebecker M, Alba-Domínguez M, Roumenina LT, et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 2013;191(2):912-21
   PubMed Web of Science ®Google Scholar
• Qiao Q, Teng X, Wang N, et al. A novel CRIg-targeted complement inhibitor protects cells from complement damage. FASEB J 2014;28(11):4986-99
   PubMedGoogle Scholar
• Feussner A, Kalina U, Hofmann P, et al. Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema. Transfusion 2014;54(10):2566-73
   PubMed Web of Science ®Google Scholar
• Lunn M, Santos C, Craig T. Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety. J Blood Med 2010;1:163-70
   PubMedGoogle Scholar
• DeZern AE, Uknis M, Yuan X, et al. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. Exp Hematol 2014;42(10):857-61
   PubMedGoogle Scholar
• Lindorfer MA, Pawluczkowycz AW, Peek EM, et al. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010;115(11):2283-91
   PubMed Web of Science ®Google Scholar
• Paixao-Cavalcante D, Torreira E, Lindorfer MA, et al. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. J Immunol 2014;192(10):4844-51
   PubMedGoogle Scholar
• Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol 2013;735:1-22
   PubMed Web of Science ®Google Scholar
• Taube C, Thurman JM, Takeda K, et al. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci USA 2006;103(21):8084-9
   PubMedGoogle Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT01602120 [1 April 2015]
   Google Scholar
• Bansal R. Novelmed Therapeutics. Anti-properdin antibodies. US8435512; 2013. Available from: http://www.freepatentsonline.com/8435512.html [ [7 May 2013]
   Google Scholar
• Novelmed Therapeutics. Available from: http://www.novelmed.com/ProductPipeline/ParoxysmalNocturnalHemoglobinuria(PNH).aspx [5 April 2015]
   Google Scholar
• Altmann E, Hommel U, Lorthiois ELJ, et al. Indole compounds or analogs thereof as complement factor D inhibitors useful for the treatment of age-related macular degeneration and their preparation. From PCT Int. Appl WO093101; 2012. Available from: http://www.google.com/patents/WO2012093101A1?cl=en&hl=it [ [12 July 2012]
   Google Scholar
• Dechantsreiter MA, Grob JE, Mac Sweeney A, et al. Preparation of quinazoline compounds as modulators of the complement alternative pathway for treating macular degeneration, diabetic retinopathy, and other diseases. From PCT Int. Appl WO192345. 2013. Available from: http://www.google.com.ar/patents/WO2013192345A1?cl=en&hl=it [ [27 December 2013]
   Google Scholar
• Morgan BP, Thanassi J, Podos S, et al. Novel small-molecule inhibitors targeting complement factor D for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014;124:4817
   Web of Science ®Google Scholar
• Wiles J, Podos S, Thanassi J, et al. Preclinical evaluation of orally bioavailable small-molecule inhibitors of complement factor D as potential treatment for paroxysmal nocturnal hemoglobinuria. Blood 2014;124:4819
   Web of Science ®Google Scholar
• Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014;123(26):4015-22
   PubMed Web of Science ®Google Scholar
• Scwaeble WJ. The utility of lectin pathway inhibitors as modulators if inflammatory, thrombotic and haemolytic diseases [abstract 25]. Paper presented at: 7th International Conference on Complement Therapeutics. 6 – 11 June 2014; Olympia; Aegean Conferences 82
   Google Scholar
• Reis ES, Falcao DA, Isaac L. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol 2006;63(3):155-68
   PubMed Web of Science ®Google Scholar
• Botto M, Kirschfink M, Macor P, et al. Complement in human diseases: lessons from complement deficiencies. Mol Immunol 2009;46(14):2774-83
   PubMedGoogle Scholar
• Luzzatto L, Hollak CE, Cox TM, et al. Rare diseases and effective treatments: are we delivering? Lancet 2015;385(9970):750-2
   PubMed Web of Science ®Google Scholar
• Patel H, Smith RA, Sacks SH, Zhou W. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 2006;17(4):1102-11
   PubMed Web of Science ®Google Scholar